Concentrations of protease inhibitors in cord blood after in utero exposure.

Published

Journal Article

OBJECTIVE: To determine the concentrations of protease inhibitors in cord blood after prenatal protease inhibitor use by pregnant women. DESIGN: Retrospective analysis of samples collected in a clinical trial. METHODS: Protease inhibitor concentrations were measured in cord blood samples collected from women enrolling in the PACTG 316 study who were receiving prenatal protease inhibitor antiretroviral therapy. RESULTS: In cord blood samples from 68 women treated with protease inhibitors during pregnancy, the concentration of these drugs was below the assay lower limit of detection in most samples, including all samples from women receiving indinavir (n = 21) and saquinavir (n = 8), 5 of 6 samples (83%) from women receiving ritonavir and 24 of 38 samples (63%) from women receiving nelfinavir. CONCLUSIONS: Low protease inhibitor concentrations in the fetus decrease the likelihood of teratogenic and toxic effects of these drugs but could fail to provide protection from transplacental or intrapartum transmission of HIV-1.

Full Text

Duke Authors

Cited Authors

  • Mirochnick, M; Dorenbaum, A; Holland, D; Cunningham-Schrader, B; Cunningham, C; Gelber, R; Mofenson, L; Culnane, M; Connor, J; Sullivan, JL

Published Date

  • September 2002

Published In

Volume / Issue

  • 21 / 9

Start / End Page

  • 835 - 838

PubMed ID

  • 12352805

Pubmed Central ID

  • 12352805

International Standard Serial Number (ISSN)

  • 0891-3668

Digital Object Identifier (DOI)

  • 10.1097/00006454-200209000-00010

Language

  • eng

Conference Location

  • United States